Form 8-K - Current report:
SEC Accession No. 0001140361-26-020845
Filing Date
2026-05-12
Accepted
2026-05-12 17:03:02
Documents
13
Period of Report
2026-05-12
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20073066_8k.htm   iXBRL 8-K 29500
2 EXHIBIT 99.1 ef20073066-ex99-1.htm EX-99.1 16220
6 image00001.jpg GRAPHIC 3586
  Complete submission text file 0001140361-26-020845.txt   185200

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA gyre-20260512.xsd EX-101.SCH 3859
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE gyre-20260512_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gyre-20260512_pre.xml EX-101.PRE 16040
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20073066_8k_htm.xml XML 4205
Mailing Address 12730 HIGH BLUFF DRIVE SUITE 250 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE SUITE 250 SAN DIEGO CA 92130 (858) 284-0115
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51173 | Film No.: 26969688
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)